14 rezilta yo
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size.
FIELD OF THE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size.
FIELD OF THE
FIELD OF THE INVENTION
The invention relates to compositions and methods of use of anti-histone antibodies or antigen-binding fragments thereof. In particular embodiments, the antibodies bind to human histones H2B, H3 or H4. The anti-histone antibodies are of use for diagnosis and/or therapy of a
PRIORITY CLAIM
This application is a .sctn.371 National Stage Application of PCT/GB2005/004743, filed on Dec. 9, 2005, which claims priority from GB Provisional Application Serial Numbers 0516435.5, filed on Aug. 11, 2005, and 0427138.3, filed on Dec. 10, 2004.
The present invention relates to
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size.
FIELD OF THE
FIELD OF THE INVENTION
The present invention relates to histone deacetylase inhibitors (HDACIs), to pharmaceutical compositions comprising one or more of the HDACIs, to methods of increasing the sensitivity of cancer cells to the cytotoxic effects of radiotherapy and/or chemotherapy comprising
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size.
FIELD OF THE
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1_SL.txt and is 71,342 bytes in size.
FIELD OF THE
The present invention relates to thiophene and thiazole substituted trifluoroethanone derivatives which are inhibitors of histone deacetylase (HDAC), particularly class II HDAC. The compounds of the present invention are useful for treating cellular proliferative diseases, including cancer. Further,
PRIORITY CLAIM
This application is a .sctn.371 National Stage Application of PCT/GB2006/050353, filed on Oct. 26, 2006, which claims priority from GB Provisional Application Serial Number 0522130.4, filed on Oct. 31, 2005.
BACKGROUND OF THE INVENTION
In eukaryotic cells the orderly packaging of DNA
SEQUENCE LISTING
The instant application contains a Sequence Listing which has been submitted in ASCII format via EFS-Web and is hereby incorporated by reference in its entirety. Said ASCII copy, created on Feb. 10, 2014, is named IMM342US1 SL.txt and is 71,342 bytes in size.
FIELD OF THE
FIELD OF THE INVENTION
The field of the invention pertains to activators of class I histone deacetylases and their uses in the treatment of neurological disorders.
BACKGROUND OF THE INVENTION
In a variety of neurodegenerative disorders such as ischemia and Alzheimer's disease (Hayashi et al.,
FIELD OF THE INVENTION
The present invention relates to histone deacetylase (HDAC) inhibitors, to pharmaceutical compositions comprising one or more of the HDAC inhibitors, to methods of increasing the sensitivity of cancer cells to the cytotoxic effects of radiotherapy and/or chemotherapy
FIELD OF THE INVENTION
The present invention relates to histone deacetylase (HDAC) inhibitors, to pharmaceutical compositions comprising one or more of the HDAC inhibitors, to methods of increasing the sensitivity of cancer cells to the cytotoxic effects of radiotherapy and/or chemotherapy